Agree !! and no apology either. With past PR's and company

New Post Public Reply Private Reply Replies (0) Message Board
GMIN tc2000chartreader #24323
308
Agree !! and no apology either. With past PR's and company expectations we should have seen results by now!! Increased debt, no revenue , no listing, major dilutions, note conversions due to missed predictions, litigation, poor agreements , (promised) dividend reduction due to miscalculated deals .......and the list goes on.
It appears Management unable to convince potential institutional support for whatever reason........a swiss cheese has less holes.
Ten year data didn't generate $$$, maybe 11 years will ??? I can understand why China is interested, they have an opportunity to own COVID IP for a few million.
John Ratcliffe said it well :
"China robs US companies of their intellectual property, replicates the technology, and then replaces the US firms in the global marketplace".
Hopefully von Hofe will generate the necessary funds/excitement to expedite Nasdaq listing.
Pfizer and Moderna are on the right track , regardless 90 or 95% efficacy, the economy is moving forward and they were able to capitalize on the hype/vaccine. By summer Covid will be less of a concern, vaccine prices down and more options for the public.
Not bashing, not frustrated , not mad lol. I look at all the info , positive / negative and at this point I'm skeptical !!
3

Generex Biotechnology Corp. (GNBTQ) Stock Research Links

GNBTQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Investment Insights: Primoris Services Earnings Outlook

Updated Category News Views 130

Understanding Primoris Services Earnings Report Expectations Primoris Services (NASDAQ: PRIM) is set to unveil its quarterly earnings report. This upcoming release is being closely monitored by investors, eager to gauge the company's financial health and future guidance. Analysts are optimistic about Primoris Services, projecting an earnings per share (EPS) of $1.32 for...

Continue Reading
Evolent Health's Valuation Insights and Growth Potential Explored

Updated Category News Views 156

Evolent Health's Stock Valuation Insights Barclays reaffirmed its Overweight rating with a price target of $39.00 for Evolent Health (NYSE: EVH) recently. This kind of optimism signals that the company's specialty care management model is no ordinary player—it’s resilient in a world where value-based care (VBC) contracting strategies are all the rage in healthcare....

Continue Reading
JOYY's Impressive Third Quarter Growth Highlights Success

Updated Category News Views 250

JOYY Reports Significant Financial Growth in Third Quarter 2025 SINGAPORE — JOYY Inc. (NASDAQ: JOYY), a leading global technology company, has announced impressive financial results for the third quarter of 2025. The report highlights a notable increase in revenue, indicating the company's strong market position and growth trajectory. Strong Revenue Performance In the...

Continue Reading
Muinmos Earns Esteemed Award for KYC Solutions Excellence

Updated Category News Views 196

Muinmos Shines at Global Forex Awards Muinmos has achieved a remarkable feat by being recognized as the Best KYC Provider at the prestigious B2B Global Forex Awards. This accolade marks the company's third consecutive victory in this category, affirming its status as a leader in client onboarding technology. The award is a testament to Muinmos’ commitment to delivering...

Continue Reading
Beverly Hills Flourishes with New Luxury Attractions and Events

Updated Category News Views 384

Exciting Transformations in Beverly Hills for 2026 Beverly Hills is stepping into a vibrant era as it gears up for a significant year. Known for its glamour and global reputation, the city is enhancing its allure through newly opened hotels, restaurants, and cultural experiences. These developments underscore its position as a premier destination, attracting luxury brands...

Continue Reading